Abstract
110 years after the classical study by Noon, numerous studies have confirmed the efficacy of allergen immunotherapy. A variety of clinical endpoints have been used in these trials. This review gives an overview of clinical endpoints for randomized clinical trials on allergen immunotherapy (AIT) in rhinitis and asthma. In addition, real-life studies have been carried out with the same kind of endpoints. In general, AIT studies are characterized by a lack of standardized and validated outcome measures. For allergic rhinoconjunctivitis, digital tools have been developed to monitor patients. Such tools are particularly useful to obtain real-world evidence for AIT. Finally, well-accepted outcome measures are available for cost-effectiveness studies.
| Original language | English |
|---|---|
| Pages (from-to) | 39-46 |
| Number of pages | 9 |
| Journal | Allergologie |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Mar 2023 |
Bibliographical note
Publisher Copyright:© 2023 Dustri-Verlag Dr. Karl Feistle. All rights reserved.
Fingerprint
Dive into the research topics of 'Clinical endpoints in allergen immunotherapy: State of the art 2022'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver